10-Q: Claritev Q3 2025: Revenue Growth Amid Refinancing & ERP Rollout

Claritev Corporation reports improved net loss and operating income in Q3 2025, driven by revenue growth and absence of goodwill impairment, while navigating a major debt refinancing and ERP system implementation.

Summary

• Net loss significantly improved to $(69.75) million for Q3 2025, compared to $(391.45) million in Q3 2024, primarily due to the absence of goodwill impairment.
• Operating income turned positive at $10.07 million for Q3 2025, a substantial improvement from an operating loss of $(338.21) million in Q3 2024.
• Revenues increased by 6.7% to $245.96 million for Q3 2025, primarily driven by Network-Based Services (+14.6%) and Analytics-Based Services (+4.2%).
• For the nine months ended September 30, 2025, net loss improved to $(203.71) million from $(1,507.87) million in the prior year, largely due to the absence of goodwill impairment charges.
• Adjusted EBITDA increased by 9.5% to $155.13 million for Q3 2025 and by 3.7% to $451.23 million for the nine months ended September 30, 2025.
• The company completed a significant Refinancing Transaction on January 30, 2025, incurring $7.9 million in transaction costs during the nine-month period.
• Cash and cash equivalents increased to $39.15 million as of September 30, 2025, from $16.85 million at December 31, 2024.
• Total shareholders' equity shifted to a deficit of $(101.84) million as of September 30, 2025, from a positive $84.02 million at December 31, 2024.

Sentiment

Score: 6

Explanation: The significant improvement in net loss and operating income is a strong positive, largely due to the absence of prior-year impairment charges. Revenue growth and increased Adjusted EBITDA also indicate operational improvements. However, the shift to a shareholder deficit, increased interest expense, and substantial G&A expenses (including transformation costs) temper the overall positive sentiment. The ongoing litigation and risks associated with ERP implementation and international expansion also add a layer of caution.

Positives

• Significant improvement in net loss for both the three and nine months ended September 30, 2025, primarily due to the absence of goodwill and intangible asset impairment losses ($0 in 2025 vs. $361.6 million in Q3 2024 and $1,434.4 million in 9M 2024).
• Operating income turned positive to $10.07 million in Q3 2025, a substantial recovery from a $338.21 million operating loss in Q3 2024.
• Revenue growth of 6.7% in Q3 2025 and 2.9% for the nine months ended September 30, 2025, driven by strong performance in Network-Based Services (+14.6% in Q3) and Payment and Revenue Integrity Services (+8.9% in 9M).
• Adjusted EBITDA increased by 9.5% in Q3 2025 and 3.7% in the nine months ended September 30, 2025, indicating improved operational profitability excluding certain non-core items.
• Successful completion of a major Refinancing Transaction on January 30, 2025, restructuring significant portions of the company's debt.
• Initiated first international market expansion into the Middle East and North Africa (MENA) region through a strategic partnership with Claims Care Revenue Cycle Management LLC.
• Maintained compliance with all debt covenants as of September 30, 2025.

Negatives

• Adjusted EPS decreased to $1.48 in Q3 2025 from $2.20 in Q3 2024, and to $4.13 in 9M 2025 from $7.09 in 9M 2024.
• Total shareholders' equity moved into a deficit of $(101.84) million as of September 30, 2025, from a positive $84.02 million at December 31, 2024.
• Interest expense increased significantly by 23.8% in Q3 2025 and 19.4% in 9M 2025, primarily due to non-cash interest on new notes and increased average indebtedness.
• Cash flows from operating activities decreased by $90.0 million for the nine months ended September 30, 2025, primarily due to lower earnings (adjusted for non-cash items) and unfavorable changes in working capital, including $71.8 million in Refinancing Transaction expenses.
• General and administrative expenses increased substantially by 64.1% in Q3 2025 and 54.4% in 9M 2025, driven by $29.5 million in transformation costs, increased personnel expenses, and losses on disposal of assets.
• Analytics-Based Services revenues decreased by 0.6% for the nine months ended September 30, 2025, primarily due to a $15.8 million decrease in Surprise Bill Services related to customer and program attrition.
• Potential medical cost savings identified decreased by 3.6% in Q3 2025, and the percentage of savings as a function of charges also declined from 14.2% to 13.3%.

Risks

• Operating in a litigious environment, with healthcare providers increasingly resistant to cost management techniques and engaging in lawsuits, including antitrust claims, which could materially adversely affect financial results and business practices.
• Ongoing implementation of a new ERP system (SAP) is complex, labor-intensive, and time-consuming, posing risks of delays, cost overruns, disruption to operations, and potential material weaknesses in internal control over financial reporting.
• International expansion into the MENA region introduces various risks, including difficulties managing geographically dispersed operations, operating in new markets, compliance with U.S. and international laws (e.g., Foreign Corrupt Practices Act, anti-money laundering), foreign regulations, limitations on partnerships, taxes, recruiting, labor laws, political and economic instability, intellectual property protection, government subsidies for competitors, currency fluctuations, and less developed infrastructure.
• Dependence on a few large customers, with three clients accounting for 28%, 11%, and 10% of revenue for the nine months ended September 30, 2025; the loss of one or more could have a material adverse effect.
• Exposure to interest rate risk on floating rate debt, despite hedging instruments, could lead to volatility in interest payments.
• The Refinancing Transaction will increase taxable income for 2025, with an estimated income tax liability of $50 million to $60 million.
• The unvested founder shares and private placement warrants were forfeited and cancelled on October 8, 2025, as the stock price re-vesting condition of $500.00 per share was not met.

Future Outlook

The company anticipates sufficient liquidity for the next twelve months from internally generated funds and its 2025 Revolving Credit Facility. Future liquidity and ability to fund capital expenditures, working capital, and debt requirements are dependent on future financial performance and the availability of additional financing, which may be sought through senior secured credit facilities, other indebtedness, or additional equity financings. The company will continue to monitor the impact of the One Big Beautiful Bill Act (OBBBA) on its tax position.

Management Comments

• We believe our solutions provide a strong value proposition to payors, their health plan customers and healthcare consumers, as well as to providers.
• Our service offerings aim to reduce healthcare costs in a manner that is orderly, efficient, and fair to all parties.
• Because in most instances the fee for our services is linked to the savings we identify, our revenue model is aligned with the interests of our customers.
• We believe these lawsuits are without merit and are vigorously defending the Company.
• We believe these sources will provide sufficient liquidity for us to meet our working capital, and capital expenditure and other cash requirements for the next twelve months.

Industry Context

Claritev operates in the U.S. healthcare industry, providing data-driven cost management solutions to payors. The industry faces continuous evolution in regulations and increasing resistance from healthcare providers to cost management techniques, leading to a litigious environment. Claritev's international expansion into the MENA region suggests a strategy to diversify revenue streams and leverage its technology platform in new markets, potentially driven by similar healthcare cost pressures abroad. The company's focus on "data-driven algorithms and insights" and "modern methods of data science" aligns with broader industry trends towards digital transformation and analytics in healthcare.

Comparison to Industry Standards

• The filing does not provide specific comparisons to comparable companies, projects, or results within the industry. It focuses solely on Claritev's internal performance and strategic initiatives.

Legal Proceedings

• The company is a defendant in various lawsuits and regulatory investigations in the ordinary course of business, including putative class action lawsuits alleging antitrust violations related to suppressing out-of-network reimbursements.
• These antitrust lawsuits have been centralized in the Northern District of Illinois, and motions to dismiss were granted in part and denied in part on June 3, 2025, with discovery ongoing.
• The company settled 2014 litigation with a dialysis company on July 11, 2024, receiving $9.8 million from insurers, with the settlement payment completed on October 7, 2024.
• The company believes the antitrust lawsuits are without merit and is vigorously defending itself.

Stakeholder Impact

• Shareholders: Experienced a 1-for-40 reverse stock split on September 20, 2024. Total shareholders' equity moved into a deficit position. Unvested founder shares and private placement warrants were forfeited.
• Employees: Personnel costs increased in G&A, and stock-based compensation increased. Employees are involved in the Vision 2030 transformation program and ERP implementation.
• Customers (Payors): Benefit from the company's cost management solutions, with identified potential medical cost savings of $18.6 billion for the nine months ended September 30, 2025. Some customer and program attrition was noted in Analytics-Based Services.
• Creditors: The company completed a significant Refinancing Transaction, restructuring its debt. The company is in compliance with all debt covenants.
• Healthcare Providers: Are increasingly resistant to cost management techniques and are engaging in litigation against the company and insurers.

Next Steps

• Continue post-implementation activities for the new ERP system (SAP).
• Monitor the impact of the One Big Beautiful Bill Act (OBBBA) and anticipated guidance from the U.S. Department of the Treasury.
• Continue to evaluate the impact of new accounting standards (ASU 2023-09, ASU 2024-03, ASU 2025-05, ASU 2025-06).
• Continue to vigorously defend against antitrust lawsuits.
• Collaborate with Claims Care on a comprehensive product roadmap for the MENA market and transition certain offshore business processes.
• Potentially purchase, redeem, or retire long-term debt at management's discretion.
• Seek additional financing if required, through borrowings or equity.

Key Dates

Recommendation

While the significant improvement in net loss and operating income is positive, it's largely due to the absence of prior-year impairment charges rather than a dramatic shift in core profitability. Revenue growth is modest, and Adjusted EPS declined. The company has successfully refinanced its debt, but interest expenses remain high, and the balance sheet shows a shift to a shareholder deficit. Ongoing transformation costs, ERP implementation risks, and significant antitrust litigation create uncertainty. The international expansion offers potential, but also new risks. A "hold" recommendation reflects the mixed financial signals and the balance between operational improvements and significant ongoing challenges and risks.

Keywords

Healthcare cost management, SEC filing, 10-Q, Claritev Corporation, CTEV, Financial results, Revenue integrity, Analytics-based services, Network-based services, Debt refinancing, ERP system, Goodwill impairment, Adjusted EBITDA, Healthcare industry, Risk factors, International expansion, Litigation, Corporate governance